- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02073435
A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
A2ALL-Patients Safety System Improvements in Living Donor Liver Transplant
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is an observational as well as a time-controlled study to be conducted at four participating A2ALL Deux Transplant Centers (TCs). The study is divided into three phases: an observational phase (Aim 1) to conduct a comprehensive and proactive patient safety risk assessment to describe preventable complications, near miss events, medical errors and hazardous conditions and in the delivery of standard of care to living donor liver transplant (LDLT) donors and recipients from the time of admission for the LDLT surgery through discharge after LDLT surgery. The in depth observational phase continues throughout the study and is scheduled to be completed by the end of the study (May 2015).
In phase 2-solution development and implementation phase (Aim 2): two high priority areas of care were identified for in depth assessment and solution development. The selection of the two high priority areas of LDLT standard of care was guided by the identification of vulnerabilities in the systems and processes of care with a high incidence and severity of related preventable complications and medical errors across the four participating A2ALL Deux TCs. To date, multiple priority areas were identified, based on the ongoing review of medical records (e.g., transition of care, glucose control, donor pain management, preoperative OR set-up). The participating A2ALL Deux TCs agreed to focus on an in depth assessment of the two areas that demonstrated high incidence and high severity of preventable complications and medical errors: 1) donor pain management and 2) preoperative OR set-up process.
Donor Pain Management:
Upon further investigation, it was identified that living liver donors experience significant amount of pain, in the early postoperative period but also especially a few days after donation. Data from the four participating A2ALL Deux TCs reveal a 20% incidence, overall, of respiratory complications (e.g. re-intubation, requirement for application of Naloxone, etc.) directly related to the opioid use in the present LDLT standard of care for donor pain management. Based on these data, clinicians at the four participating A2ALL Deux TCs, in consultation with an international pain expert with particular expertise in transplantation (Paul White, MD University of Texas Southwestern Medical Center at Dallas, Dallas, Texas), developed an evidence-based donor pain management solution with the aim of reducing preventable complications as well as improving the donor pain experience. This evidence-based donor pain management solution was developed over months through in-person and telephone meetings of transplant surgeons, hepatologists, anesthesiologists and acute pain specialists from all four participating A2ALL Deux TCs, in addition to the research teams. Consensus has been reached on the key elements of the evidence-based donor pain management solution and all four participating A2ALL Deux TCs are poised to begin implementation.
- Preoperative OR Set-up Process:
Preventable complications, near miss events, medical errors and hazardous conditions related to the preoperative OR set-up processes were identified. The four participating A2ALL Deux TCs will need to engage in additional review of the detailed assessment of the standardization and optimization of the preoperative OR set-up process and then, will collaboratively design a standardized process over a four month period (expected conclusion mid February 2014 in order to incorporate what occurs at the Collaborative at each site and overall). Solutions will be designed collaboratively to reduce the incidence and severity of related medical errors and preventable complications together with the TCs and their staff.
The measurement of solution impact to reduce preventable complications and medical errors (Aim 3) involves the implementation of the two collaboratively developed solutions: (1) Evidence-based donor pain management solution and (2) Standardization and optimization of the preoperative OR set-up process. During this phase relevant metrics pre- and post-implementation will be compared to assess the effectiveness of the implemented solutions.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
-
Massachusetts
-
Burlington, Massachusetts, Stati Uniti, 01805
- Lahey Clinic
-
-
New York
-
New York, New York, Stati Uniti, 10032
- Columbia University
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23298
- Virginia Commonweath University-Medical College of Virginia
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
CLINICIANS: All clinicians who are involved in the inpatient care provided to the LDLT A2ALL donors and recipients are eligible for the study. The group of clinicians eligible for the study involve all clinicians participating in the LDLT care between day of surgery through discharge: OR personnel (nurses, technicians, anesthesiologists, surgeons, research staff, cell saver staff, etc.), PACU/Intensive Care Unit personnel (nurses, anesthesiologists, surgeons, pharmacists, etc.) and floor personnel (nursing, coordinators, pharmacists, etc.).
PATIENTS: Living Donor Liver Transplant patients (donor and recipients) from 2008-2015.
Descrizione
Inclusion Criteria:
A. Clinicians
- Clinicians of both genders, of any race/ethnicity are included. Only clinicians who are unwilling to participate will be excluded.
- Clinicians and staff who are involved in the care of LDLT donors and recipients (e.g., nurses, surgeons, anesthesiologists, hepatologists, unit secretaries from medical and surgical units, ICU, transplant coordinators, pharmacists) at the four participating A2ALL Deux TCs.
B. Patients
- Every donor (≥ 21 years) and recipient involved in LDLT at the four participating A2ALL Deux TCs between 2004-2015, who were enrolled into the A2ALL cohort study Un and/or Deux. (However, to date medical record reviews were only performed for patients involved in LDLTs 2008 or later. Observations were initiated in December, 2011). After enrollment of patients into the A2ALL Deux cohort study ends (anticipated May 2014), all LDLT donors and recipients at the four participating A2ALL Deux TCs will be approached for enrollment into this ancillary A2ALL R01 patient safety study.
- Patients have not been and will not be excluded on the basis of race, gender, or any other related characteristics.
Exclusion Criteria:
- No participants will be under 21 years of age. Patients will not be excluded on the basis of age, race, gender or any other non-employment related characteristics
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Post-Implementation Group
Living Donor Liver Transplant patients with evidence based donor pain management solution.
|
The evidence-based donor pain management solution entails the following elements: Preoperative Assessment and Management:
At the end of the case in OR:
Postoperative Management:
Postoperative Assessment: o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression |
|
Pre-Implementation Group
Living Donor Liver Transplant patients prior to the implementation of the evidence based donor pain management solution.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Living Donor Pain Management
Lasso di tempo: Daily Visual Analogue Pain Scores (0-10) At transplant (post-operative day 0) and throughout hospitalization (post-operative days 1-8)
|
Comparison of Average Pain Scores on Visual Analogue Pain Scale (0-10) measured before and after implementation of evidence-based donor pain management solution.
0 representing "No Pain", up through 10 representing "Worst possible, unbearable, excruciating pain".
|
Daily Visual Analogue Pain Scores (0-10) At transplant (post-operative day 0) and throughout hospitalization (post-operative days 1-8)
|
|
Complications
Lasso di tempo: Perioperatively
|
Cardiopulmonary complications
|
Perioperatively
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Daniela Ladner, MD MPH, Northwestern Univesity
- Investigatore principale: Donna Woods, PhD, Northwestern University
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Insufficienza epatica
- Insufficienza epatica
- Processi patologici
- Neoplasie per tipo istologico
- Neoplasie
- Neoplasie per sede
- Adenocarcinoma
- Carcinoma
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie dell'apparato digerente
- Fibrosi
- Malattie del fegato
- Malattia epatica allo stadio terminale
- Carcinoma, epatocellulare
- Cirrosi epatica
- Neoplasie del fegato
Altri numeri di identificazione dello studio
- A2ALL Safety Study
- R01DK090129 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Malattie del fegato
-
Medical College of WisconsinRitiratoModello alto per il punteggio MELD (end-stage Liver Disease).Stati Uniti
Prove cliniche su Donor pain management
-
Shirley Ryan AbilityLabCoapt, LLCAttivo, non reclutanteAmputazione dell'arto inferiore sotto il ginocchio (lesione) | Amputazione dell'arto inferiore sopra il ginocchio (lesione) | Amputazione | Dolore agli arti fantasma | Dolore Fantasma | Sensazione fantasma | Ginocchio per amputazione degli arti inferiori | Amputazione dell'arto superiore sotto il gomito... e altre condizioniStati Uniti
-
Université de SherbrookeQuebec Pain Research NetworkCompletatoDolore lombare meccanicoCanada
-
VA Office of Research and DevelopmentReclutamento
-
Johns Hopkins UniversityCompletatoMalattia renale allo stadio terminaleStati Uniti
-
Nationwide Children's HospitalNon ancora reclutamento
-
University of ZurichETH Zurich; The University of New South WalesReclutamentoDisturbo da stress post-traumatico | Trauma | Disagio psicologico | Problemi di salute mentale comuniSvizzera
-
Cameroon Baptist Convention HealthCarolinas Medical CenterCompletato
-
University of ChilePan American Health OrganizationCompletatoDisordine depressivo | Disturbi d'ansiaChile
-
Duke UniversityCompletatoCannabis | Uso di cannabisStati Uniti
-
University of AlbertaAlberta Health services; Ontario Bioscience Innovation OrganizationCompletato